Published in:
Open Access
01-12-2021 | SARS-CoV-2 | Research Letter
YKL-40 as a new promising prognostic marker of severity in COVID infection
Authors:
Lauranne Schoneveld, Aurélie Ladang, Monique Henket, Anne-Noëlle Frix, Etienne Cavalier, Julien Guiot, the COVID-19 clinical investigators of the CHU de Liège
Published in:
Critical Care
|
Issue 1/2021
Login to get access
Excerpt
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for a disease named COVID-19, which may be associated with common symptoms or lead patients to intensive care unit (ICU) or death. The severity of the disease is mainly driven by diffuse interstitial lung diseases (ILD). YKL-40 has a promitogenic action on pulmonary fibroblasts, increases the activity of macrophages and is associated with inflammatory disorders, arteriosclerosis and endothelial dysfunction. In ILD, YKL-40 has been described to be associated with the severity of lung diseases and with the risk of death [
1‐
6]. Yet, in COVID-19 infection, YKL-40 serum levels could therefore be of interest for diagnosis and prognosis since it is at the cross-link between vascular and epithelial lung damage, which are typical characteristics of COVID-19 infection. By closing the gap between those two pathological characteristics, we thought that YKL-40 could be of interest a specific biomarker of severe COVID-19 infection. …